Back

Impact of mavacamten on left atrial remodeling in obstructive hypertrophic cardiomyopathy: data from 3 portuguese centers

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ines Miranda

Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)

5 More presentations in this session

Presentation thumbnail
One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy
Doctor G. Bonacchi (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation during mavacamten treatment in obstructive hypertrophic cardiomyopathy in the real-world: data from the multicenter MARVEL.HU registry on 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort
Doctor D. Jensen (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Real-world experience with mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy
Doctor S. Hoss (Petah Tikva, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibition in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of mavacamten on left atrial remodeling and function in obstructive hypertrophic cardiomyopathy. A real-world multicentric prospective study.
29 August 2026
thumbnail
Congress Presentation
Importance and significance of left atrial reverse remodelling in the follow-up of patients with heart failure
28 August 2026
thumbnail
Congress Presentation
Baseline global longitudinal strain and mechanical dispersion predict ejection fraction decline during mavacamten therapy in obstructive hypertrophic cardiomyopathy
29 August 2026
thumbnail
Congress Presentation
Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathy
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources